The effect of heparin gel in improving hand and foot syndrome in patients treated with capecitabine

Survey the effect of topical heparin gel on the improvement of hand and foot syndrome in cancer patients treated with capecitabine

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230215057423N1

Enrollment

Registered

2023-05-01

Start date

2023-04-30

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer patient. Malignant neoplasm of connective and soft tissue of head, face and neck

Interventions

Intervention 1: Intervention group: Intervention group: Group A as the intervention group, in addition to the standard chemotherapy treatment, will receive heparin sulfate gel 40 mg 4 times a day for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Newly diagnosed cancer patients for gastrointestinal tract and head and neck cancer treated with capecitabine and have evidence of early onset of hand-foot syndrome (grade 1 from onset)

Exclusion criteria

Exclusion criteria: The patient already has a skin or inflammatory disease The patient's unwillingness to start the trial

Design outcomes

Primary

Measure	Time frame
Examination of erythema, blisters and hyperkeratosis in hand and foot syndrome. Timepoint: Day zero and day twenty one. Method of measurement: Questionnaire and observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaede Mirjalili

Shahre-kord University of Medical Sciences

maedemirjalili98@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026